Hims & Hers Stock Jumps 85.1% in 3 Months: Is It a Buy Now?

Key Takeaways HIMS stock surged 85.1% in three months, outperforming its industry, sector and major competitors. HIMS' new deals include a ZAVA buyout, a Novo Nordisk partnership and $870 million convertible notes offering. HIMS expects up to 74% second-quarter revenue growth and aims to expand AI-powered care across global markets.Hims & Hers Health, Inc.’s (HIMS) investors have been experiencing some short-term gains from the stock lately despite its bumpy ride over recent months. The San Francisco, CA- ...